Bruno Almeida

  • Neurodegeneration
  • Diagnostics
  • Biochemistry
  • Sensors
  • Structural biology

Bruno Almeida (BA) has a B.Sc. in Applied Biology and a Ph.D. in Health Sciences from the University of Minho. BA has several competencies in neurodegeneration, structural biology, biochemistry, biophysics, molecular and cell biology, and microbiology. BA conducted research in several top national (ICVS and I3S) and international institutions, such as Leiden University, Oulu University, EMBL, ESRF Grenoble, PRBB and Universitat de Barcelona. He is an author of 17 papers and 1 book chapter with an accumulated impact factor of 136 and with over 1250 citations conferring an h index of 13. BA was also involved during 6 years in teaching nursing and medical students at the University of Minho. BA is currently interested in studying disease targets and in the development of diagnostic and therapeutic tools. BA participated in 10 funded research projects, including EU-financed projects, and has 1 international patent application (PCT application). As principal investigator, BA secured funding from a pan-European institution (Instruct). BA supervised 1 PhD student, 1 MSc student, and 11 BSc students, and co-supervised 2 MSc students. BA contributed to 10 oral presentations (2 as an invited speaker) and 23 poster presentations in national and international conferences. In the last years, BA has been involved in the development of a new generation of diagnostic devices that lead to the creation of IPLEXMED in 2021, a spin-off from INL/ICVS-UMinho. BA is currently the CEO of IPLEXMED, which already attracted 220k euros in grants and won the 7th Acceleration program from Startup Braga.

Scientific Highlights

Silva, A., Almeida, B., Fraga, J. S., Taboada, P., Martins, P. M., & Macedo-Ribeiro, S. (2017). Distribution of Amyloid-Like and Oligomeric Species from Protein Aggregation Kinetics. Angewandte Chemie (International ed. in English), 56(45), 14042–14045.

Scarff, C. A., Almeida, B., Fraga, J., Macedo-Ribeiro, S., Radford, S. E., & Ashcroft, A. E. (2015). Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion. Molecular & cellular proteomics: MCP, 14(5), 1241–1253.

Almeida, B., Abreu, I. A., Matos, C. A., Fraga, J. S., Fernandes, S., Macedo, M. G., Gutiérrez-Gallego, R., Pereira, P. J., Carvalho, A. L., & Macedo-Ribeiro, S. (2015). SUMOylation of the brain-predominant Ataxin-3 isoform modulates its interaction with p97. Biochimica et Biophysica acta, 1852(9), 1950–1959.

Cunha, C., Aversa, F., Lacerda, J. F., Busca, A., Kurzai, O., Grube, M., Löffler, J., Maertens, J. A., Bell, A. S., Inforzato, A., Barbati, E., Almeida, B., Santos e Sousa, P., Barbui, A., Potenza, L., Caira, M., Rodrigues, F., Salvatori, G., Pagano, L., Luppi, M., … Carvalho, A. (2014). Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. The New England Journal of Medicine, 370(5), 421–432.

Funding and Awards
CEO and Co-founder of IPLEXMED, a spin off company that develops the new generation of fast, portable, and connectable laboratory-grade diagnostic devices

Winner of “Empreender Braga” 2021 – pre-acceleration program from Startup Braga – IPLEXMED New Generation Diagnostics. IPLEXMED. CEO & Co-founder

Winner of “7th Startup Braga Acceleration program” 2022 – IPLEXMED New Generation Diagnostics. IPLEXMED. CEO & Co-founder

Winner of the BfK – Born from Knowledge Award from ANI, Agência Nacional de Inovação – IPLEXMED. CEO & Co-founder

Finalist of the AIIA – Altice International Innovation Award 2022. IPLEXMED. CEO & Co-founder

Graphene-based malaria sensor, methods and uses thereof. International Patent Application no: PCT/IB2022/051743